This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
synovial-sarcoma
Synovial Sarcoma
Synovial sarcoma is defined by SS18-SSX1/SSX2 fusion (t(X;18)) → SMARCB1 displacement from BAF → EZH2 dependency; ~800/year USA; biphasic/monophasic histology; TLE1 IHC positive; ifosfamide-based chemotherapy; tazemetostat (SARC057 ORR ~22%) and trabectedin active.
Entry Metadata
| Field | Value |
|---|---|
| ID | synovial-sarcoma |
| Name | Synovial Sarcoma |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153(1):71-85. · PubMed 23540691
- Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015;16(4):406-416. · PubMed 25795407